New drug duo aims to outsmart returning blood cancer
NCT ID NCT04324112
Summary
This study is testing if a combination of two oral drugs, encorafenib and binimetinib, works better than a previous single drug for adults with hairy cell leukemia that has a specific genetic change (BRAF V600 mutation) and has come back or stopped responding to standard treatment. The goal is to see if this drug pair can achieve a higher rate of complete remission and potentially be better tolerated. Participants will take the pills daily in 28-day cycles for as long as it is effective and safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HAIRY CELL LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.